GlobeNewswire PharmaOriginal article
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
ConferenceIHEEZO®BYOOVIZ®LUCENTISPositive
AI Analysis
Summary
Harrow presented three clinical studies supporting IHEEZO® and BYOOVIZ® at the ASRS 2026 Annual Meeting, expanding evidence for its retina portfolio.
Outcome Details
Presentation of three studies at ASRS 2026 Annual Meeting
Importance:4/10
Sentiment:
0.50
conferenceclinical evidenceophthalmicretinabiosimilarASRS 2026
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 20, 2026 11:00 AM